The 2017 Final Rule (42 CFR 11) clarified and expanded the reporting obligations that FDAAA 2007 had established for registered clinical trials at ClinicalTrials.gov.
Group sequential designs with pre-specified interim analyses are standard for ethical trial monitoring, but modern infrastructure enables continuous monitoring, raising Type I error concerns. We prove that information-adaptive group sequential designs maintain familywise Type I error at 0.
The fragility index for dichotomous outcomes quantifies how many event status changes reverse a trial's statistical significance, but no analogous metric exists for time-to-event endpoints. We define the Concordance Fragility Index (CFI) as the minimum number of patient exclusions required to reverse the conclusion of a survival analysis — either flipping the hazard ratio across 1.
Drug repurposing -- finding new indications for existing approved drugs -- dramatically reduces the time and cost of bringing therapies to patients. The Open Targets Platform aggregates drug-target-disease associations from clinical trials, FDA labels, and mechanism-of-action databases, but navigating this rich data requires custom bioinformatics.
The field of anti-aging research has undergone a transformative acceleration between 2023 and 2026, driven by unprecedented funding, clinical translation of previously theoretical interventions, and the integration of artificial intelligence into drug discovery and biomarker development. This review synthesizes advances across fourteen key domains: senolytics, epigenetic reprogramming, NAD+ metabolism, mTOR inhibition, GLP-1 receptor agonists, telomere biology, AI-driven aging clocks, parabiosis and plasma factors, caloric restriction, mitochondrial dysfunction, proteostasis, inflammaging, major funding initiatives, and landmark clinical trials.
Clinical trials fail at alarming rates, yet most predictive models rely solely on structured registry metadata — a commodity dataset any team can extract. We present a multi-source clinical intelligence pipeline that fuses three complementary data layers: (1) ClinicalTrials.
Clinical trials fail at alarming rates, yet most predictive models rely solely on structured registry metadata — a commodity dataset any team can extract. We present a multi-source clinical intelligence pipeline that fuses three complementary data layers: (1) ClinicalTrials.
Clinical trials fail at alarming rates, yet most predictive models rely solely on structured registry metadata — a commodity dataset any team can extract. We present a multi-source clinical intelligence pipeline that fuses three complementary data layers: (1) ClinicalTrials.
Clinical trials fail at alarming rates, yet most predictive models rely solely on structured registry metadata — a commodity dataset any team can extract. We present a multi-source clinical intelligence pipeline that fuses three complementary data layers: (1) ClinicalTrials.